By being vertically integrated and owning all steps of the pharmaceutical development and production process, Accord can bring high quality medicines to patients faster, more economically and with greater efficiency than our rivals.

Accord has one of the most dynamic product pipelines in the pharmaceutical industry. Already we boast a portfolio of over 130 molecules across multiple therapeutic classes. We are committed to build up this number to compete with the largest product ranges in the sector. To date, we have gained nearly 7,000 marketing authorizations across the European Economic Area.

Accord has a particular focus on ensuring the safe use of our products, both for patients and medical professionals.


Our entire range of product packaging has been designed to minimise the incidence of errors in dispensing, preparing and administering of our medicines.

Accord's portfolio comprises a multitude of different pharmaceutical forms, including; tablets (standard, film- coated, effervescent, sustained release, cytotoxic and immunosuppressant), capsules, cytotoxic injectables (powders and solution vials), non- cytotoxic (ampoules) and controlled drugs.

With oncology products, we undertake a Preventative and Protective approach to occupational exposure. All cytotoxic containing products undergo a rigorous cleaning protocol to minimise possible external residue before being wrapped in our PharmaShield ® technology.